TNF and spondylitis: This effect was observed especially in those studies that evaluated rheumatic diseases (RA, psoriatic arthritis, spondylitis), a group that became very homogeneous and presented a calculated incidence of 20.08 cases of histoplasmosis per 100,000 patients treated with a TNF-α inhibitor, similar to the traditional estimate.